Enlivex (ENLV) Q4 2023 earnings summary

Executive summary

• Clinical-stage Allocetra™ macrophage-reprogramming therapy development continued under a strategic reprioritization and cash-preservation plan approved Aug. 30, 2023.

• 2023 revenue remained $0; net loss narrowed to $29.1M from $31.1M in 2022, including a $4.244M held-for-sale impairment.

• Auditors gave unqualified opinions on the financial statements and internal control over financial reporting as of Dec. 31, 2023.

Financial highlights

• 2023 R&D expense, net, was $19.012M vs. $18.693M in 2022; G&A was $6.139M vs. $7.104M.

• Operating loss was $29.395M vs. $25.797M in 2022; net loss was $29.068M vs. $31.060M.

• Cash and cash equivalents were $813K and short-term interest-bearing deposits were $26.507M at year-end, vs. $49.945M and $299K, respectively, in 2022.

• Net cash used in operating activities was $23.523M in 2023 vs. $23.953M in 2022.

Outlook and guidance

• Management expects current financial resources to fund product-candidate development for at least 12 months after the financial statements’ filing; additional capital may be raised.

• Losses and negative operating cash flow are expected to continue for at least several years as development proceeds; longer-term plans depend on financing, partnerships or product revenue.